13 completed, 2 terminated. 10 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 10 |
| Phase 2 | 5 | Completed 3, Terminated 2 |
Follow Trio Medicines Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Selective β2-AR Antagonism in Asthma TR4, Placebo - Asthma | Phase 1 | Completed | Trio Medicines Ltd. | 12 | 2018-02-28 | 2025-12-09 |
| YF476 in Barrett's Esophagus YF476, YF476 placebo - Barrett's Esophagus | Phase 2 | Completed | Trio Medicines Ltd. | 27 | 2013-05-15 | 2021-04-12 |
| YF476 and Type I Gastric Carcinoids (Norway) YF476 - Chronic Atrophic Gastritis, Hypergastrinemia | Phase 2 | Terminated | Trio Medicines Ltd. | 8 | 2011-06-01 | 2015-05-15 |
| YF476 and Type II Gastric Carcinoids YF476 - Zollinger-Ellison Syndrome | Phase 2 | Terminated | Trio Medicines Ltd. | 3 | 2011-04-11 | 2021-01-29 |
| YF476 and Type I Gastric Carcinoids YF476 - Chronic Atrophic Gastritis, Hypergastrinaemia | Phase 2 | Completed | Trio Medicines Ltd. | 8 | 2011-01-04 | 2019-08-19 |
| Trial of a Gastrin Receptor Antagonist in Barrett's Esophagus YF476, Placebo - Barrett's Esophagus | Phase 2 | Completed | Columbia University | 27 | 2010-06-01 | 2021-11-23 |
| Effect of Netazepide on Omeprazole-induced Changes in Chromogranin A and Gastrin netazepide - ECL-cell Hyperplasia, Parietal-cell Hyperplasia | Phase 1 | Completed | Trio Medicines Ltd. | 48 | 2009-11-01 | 2015-12-03 |
| Effects of YF476 and Rabeprazole on Gastric Function YF476, Rabeprazole - Hypergastrinaemia | Phase 1 | Completed | Trio Medicines Ltd. | 32 | 2006-08-01 | 2012-10-03 |
| Effect of Repeated Doses of YF476 on Stomach Acidity YF476, Placebo - Hypergastrinaemia | Phase 1 | Completed | Trio Medicines Ltd. | 10 | 2001-10-01 | 2012-05-18 |
| Effect of Single Doses of YF476 on Stomach Acidity YF476, Placebo - Hypergastrinaemia | Phase 1 | Completed | Trio Medicines Ltd. | 12 | 2001-10-01 | 2012-05-18 |
| Avonex®: Safety, Blood Levels and Effects Interferon beta 1a, (IM) AVONEX® - Multiple Sclerosis (MS) | Phase 1 | Completed | Trio Medicines Ltd. | 77 | 2001-01-01 | 2013-05-27 |
| Effect of 5, 10 or 25 mg of YF476 Daily for 14 Days on Stomach Acidity in Healthy Volunteers YF476 - Reflux Oesophagitis | Phase 1 | Completed | Trio Medicines Ltd. | 49 | 1997-04-01 | 2012-05-14 |
| Effect of Repeated Doses of YF476, Omeprazole and Placebo on Stomach Acidity in Healthy Volunteers YF476, Omeprazole - Reflux Oesophagitis | Phase 1 | Completed | Trio Medicines Ltd. | 49 | 1996-08-01 | 2012-05-16 |
| Effect of Single Doses of YF476 on Stomach Acidity Compared With Ranitidine and Placebo in Fasted and Fed States YF476, Ranitidine - Reflux Oesophagitis | Phase 1 | Completed | Trio Medicines Ltd. | 22 | 1996-07-01 | 2012-02-24 |
| Safety, Tolerability and Pharmacokinetics of Single Rising Doses of YF476, a Gastrin Antagonist, in Healthy Men YF476 - Reflux Oesophagitis | Phase 1 | Completed | Trio Medicines Ltd. | 15 | 1996-05-01 | 2012-02-24 |
Esophagitis, Peptic (4) · Barrett Esophagus (2) · Gastritis, Atrophic (2) · Gastroesophageal Reflux (2) · Adenocarcinoma Of Esophagus (1) · Asthma (1) · Dyspepsia (1) · Multiple Sclerosis (1) · Respiratory Aspiration (1) · Zollinger-Ellison Syndrome (1)
YF 476 (13) · Interferon beta-1a (1) · Omeprazole (1) · Rabeprazole (1) · Ranitidine (1)
United Kingdom (12) · United States (2) · Norway (1)
Malcolm Boyce (6) · Malcolm Boyce, BSc FRCP FFPM (2) · Malcolm J Boyce, FRCP FFPM (2) · Denisa Wilkes (1) · Helge Waldum, MD PhD (1) · Julian A Abrams, MD MS (1) · Julian A Abrams, MD, MS (1) · Mark Pritchard, PhD FRCP (1) · Steve Warrington (1)